国家药监局：2024年全国药械妆报告数量质量稳步增长

Core Points - The meeting held on April 22, 2025, in Kunming, Yunnan, focused on the monitoring and evaluation of adverse drug reactions in China, highlighting the steady growth in the quantity and quality of reports in 2024 [1] - The meeting emphasized the importance of deepening drug regulatory reforms in 2025, which is the concluding year of the 14th Five-Year Plan, to ensure drug safety and support high-quality development of the pharmaceutical industry [1] Summary by Categories Monitoring and Evaluation - The quantity and quality of national drug and medical device reports have steadily increased in 2024, with effective utilization of monitoring and evaluation data [1] - The risk prevention and control measures have proven effective, and the monitoring system's capabilities have been further enhanced [1] Regulatory Reforms - The meeting underscored the need to strengthen the implementation of major central policy decisions and enhance responsibility in drug safety [1] - There is a focus on consolidating the "one body and two wings" work structure to improve drug safety oversight [1] Risk Control - The meeting called for enhanced risk control measures, particularly in key areas and products, to ensure comprehensive drug safety [1] - The importance of strengthening party leadership in the regulatory process was also highlighted [1]